Td Asset Management Inc Relmada Therapeutics, Inc. Transaction History

Td Asset Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	BUY	$2.48 - $3.79 $31,000 - $47,375	12,500 Added 100.0%	25,000 $75,000
Q3 2022 Nov 07, 2022	BUY	$18.3 - $37.02 $9,150 - $18,510	500 Added 4.17%	12,500 $452,000
Q2 2022 Aug 04, 2022	BUY	$16.5 - $30.34 $58,492 - $107,555	3,545 Added 41.93%	12,000 $228,000
Q1 2022 May 10, 2022	BUY	$16.72 - $26.99 $141,367 - $228,200	8,455 New	8,455 $228,000
Q1 2020 May 15, 2020	SELL	$23.78 - $50.12 $154,403 - $325,429	-6,493 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$10.1 - $47.18 $65,579 - $306,339	6,493 New	6,493 $253,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.